Medical CouncilPub Date : 2019-10-10DOI: 10.21518/2079-701x-2019-13-106-111
E. I. Ermakova
{"title":"Genitourinary menopausal syndrome: diagnosis and treatment principles","authors":"E. I. Ermakova","doi":"10.21518/2079-701x-2019-13-106-111","DOIUrl":"https://doi.org/10.21518/2079-701x-2019-13-106-111","url":null,"abstract":"Aim: Presentation of basic clinical scientific data based on modern evidence of anatomical and physiological changes in the urogenital tract in periand postmenopause and the principles of management of women with genitourinary menopausal syndrome.Material and methods: The review of domestic and foreign sources devoted to prevalence, modern diagnostics and methods of vaginal atrophy treatment was carried out.Results: the present article contains modern terminology, data on etiopathogenesis, clinic, diagnostics and treatment methods of VVA, clinical examples.","PeriodicalId":18388,"journal":{"name":"Medical Council","volume":"216 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91396724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medical CouncilPub Date : 2019-10-09DOI: 10.21518/2079-701X-2019-16-78-85
Sergey Andreevich Martynov, M. S. Shamkhalova
{"title":"Hyperphosphatemia in chronic kidney disease","authors":"Sergey Andreevich Martynov, M. S. Shamkhalova","doi":"10.21518/2079-701X-2019-16-78-85","DOIUrl":"https://doi.org/10.21518/2079-701X-2019-16-78-85","url":null,"abstract":"Hyperphosphatemia in renal pathology is a key factor for developing mineral and bone disorders. It can develop even in the early stages of renal function decline and predict the formation of vascular calcification and an increased risk for developing cardiovascular complications in patients with chronic kidney disease, especially in those, who receive program hemodialysis. The use of calcium-free phosphate-binding agents that are not associated with the risk for developing hypercalcemia can slow the development of vascular calcification, reduce the incidence of adverse cardiovascular events and mortality in patients with chronic kidney disease.","PeriodicalId":18388,"journal":{"name":"Medical Council","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77140854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medical CouncilPub Date : 2019-08-30DOI: 10.21518/2079-701x-2019-12-115-121
Larisa V. Kondratyeva
{"title":"Early combination therapy for type 2 diabetes. Time for new decisions","authors":"Larisa V. Kondratyeva","doi":"10.21518/2079-701x-2019-12-115-121","DOIUrl":"https://doi.org/10.21518/2079-701x-2019-12-115-121","url":null,"abstract":"The morbidity of diabetes mellitus is steadily increasing worldwide. Most of the patients with type 2 diabetes, many of whom already have complications when diagnosed. Strategy and tactics of treatment of patients with DM2 today are one of the priorities of modern medicine.","PeriodicalId":18388,"journal":{"name":"Medical Council","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91395766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medical CouncilPub Date : 2018-11-11DOI: 10.21518/2079-701x-2018-19-28-30
S. Menshikova, M. Frolova, E. Glazkova, M. Stenina
{"title":"Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function","authors":"S. Menshikova, M. Frolova, E. Glazkova, M. Stenina","doi":"10.21518/2079-701x-2018-19-28-30","DOIUrl":"https://doi.org/10.21518/2079-701x-2018-19-28-30","url":null,"abstract":"Treatment of choice of metastatic hormone-dependent breast cancer regardless of age is hormone therapy (HT) even with visceral metastases. Now we have a new class of drugs called inhibitors of cyclin-dependent kinases 4/6, which significantly increase effectiveness of HT and prevent development of resistance to HT. In MONALEESA-7 inhibitor of cyclin-dependent kinases 4/6 ribociclib was studied in combination with ovarian suppression and hormone therapy in young patients with preserved ovarian function, and found no differences in the efficacy and safety of these drugs compared with menopausal patients. Our clinical experience strongly demonstrates the safety and efficacy of ribociclib in combination with HT and ovarian suppression in premenopausal patient with visceral metastases.","PeriodicalId":18388,"journal":{"name":"Medical Council","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91395713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：